-transparent.png){kind=logo}
A GLC assay for phencyclidine (PCP) is described, which also simultaneously measures three primary hydroxylated metabolites formed from incubating PCP in tissue homogenates. Using the FID detector, the limits of reliable detection of PCP and both monohydroxy metabolites, 4-phenyl-4-piperidino-cyclohexanol, 2, and 1-(1-phenylcyclohexyl)-4-hydroxypiperidine, 3, are 0.02 mumol per injection and 0.05 mumol for the dihydroxy metabolite, 4-(4'-hydroxypiperidino)-4-phenylcyclohexanol, 2A. Baseline separation of an compounds was achieved and coefficients of variation (between-run) was 3-6% for PCP, and both monohydroxy metabolites, and 12% for the dihydroxy metabolite. A GCMS assay is also reported herein for the analysis of PCP at low levels, and can detect 5 pmol per injection of PCP, with a linear standard curve from 50 to 2000 pmol.
R C Kammerer, and
E Di Stefano, and
D Schmitz
October 1977,
Biomedical mass spectrometry,
R C Kammerer, and
E Di Stefano, and
D Schmitz
January 1984,
Journal of analytical toxicology,
R C Kammerer, and
E Di Stefano, and
D Schmitz
February 1970,
Journal of pharmaceutical sciences,
R C Kammerer, and
E Di Stefano, and
D Schmitz
May 1977,
Journal of chromatography,
R C Kammerer, and
E Di Stefano, and
D Schmitz
November 2004,
Clinical chemistry,
R C Kammerer, and
E Di Stefano, and
D Schmitz
May 1980,
Clinical chemistry,
R C Kammerer, and
E Di Stefano, and
D Schmitz
May 1974,
Zeitschrift fur klinische Chemie und klinische Biochemie,
R C Kammerer, and
E Di Stefano, and
D Schmitz
January 1979,
Therapie,
R C Kammerer, and
E Di Stefano, and
D Schmitz
May 1983,
Il Farmaco; edizione pratica,
R C Kammerer, and
E Di Stefano, and
D Schmitz
October 1986,
Clinical chemistry,
